• Patent application filed for proprietary probiotic strain BMB18
• Successful in-vitro study indicates BMB18's differentiated functional characteristics
• Human clinical trial with La Trobe University expected to commence in Q4 FY26
• Patent filing supports Biome's IP development strategy and competitive positioning

Biome Australia Limited (ASX: BIO) has filed its inaugural patent application for proprietary next generation probiotic strain BMB18, establishing the company's entry into intellectual property development and innovation-driven growth. BMB18 represents the first outcome of Biome's strategic initiative to develop next generation probiotic solutions that extend beyond conventional approaches. The company has invested in comprehensive strain characterisation and development capabilities, establishing a foundation for continued IP exploration across multiple therapeutic applications. Pre-clinical study has indicated BMB18's potential therapeutic properties, including immune system modulation, intestinal barrier support, and antioxidant activity. Biome's first human clinical trial on BMB18 has received ethics approvals and is expected to commence in partnership with La Trobe University in Q4 FY26. The randomised, double-blind, placebo-controlled trial aims to recruit 240 participants to further strengthen the data set on BMB18. The patent filing initiates Biome's broader intellectual property development journey, with the company building systematic capabilities in strain identification, characterisation, and validation. Future development activities will continue exploring novel strain candidates with the goal of building a portfolio of proprietary assets that differentiate Biome's offerings in the practitioner market. Biome's established mass distribution and practitioner trust create a direct pathway to market for future launches of the company's proprietary innovations, subject to clinical outcomes, regulatory considerations and commercial assessment.

Biome is committed to building sustainable IP assets while maintaining its focus on practitioner education and clinical efficacy. BMB18 is the first step on an IP exploration journey that the company believes will fundamentally differentiate its offerings in the practitioner market.